As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…
We asked a retired special operations leader about what makes effective leadership. His answer challenges everything you think you know about who gets to lead.
In large organizations, major initiatives rarely fail overnight. The real problem is that the system quietly trains people not to surface issues until the cost of fixing them becomes far greater.
Livvy Dunne built a million-dollar business from NIL deals and her social media following, partnering with brands like Accelerator Active Energy. Now, she’s shifting her focus toward equity and ownership.